Wellbutrin (bupropion) is an atypical antidepressant that works primarily by inhibiting the reuptake of dopamine and norepinephrine, distinguishing it from SSRIs and SNRIs that target serotonin. It is prescribed for major depressive disorder, seasonal affective disorder, and is also used off-label for ADHD and smoking cessation (marketed as Zyban for the latter).
The most frequently reported Wellbutrin side effects include dry mouth, insomnia (particularly if taken too late in the day), headache, nausea, dizziness, constipation, increased heart rate, and agitation or restlessness. Because bupropion has a mild stimulant-like effect through dopamine activity, insomnia and agitation are more common than with SSRIs. Taking the last dose before mid-afternoon and starting at a lower dose typically manages these effects. Unlike most antidepressants, Wellbutrin has a notably low rate of sexual side effects, making it a preferred option when sexual dysfunction from other medications is a concern.
The most clinically significant risk with Wellbutrin is a dose-dependent increase in seizure risk. At doses up to 300mg daily (the standard antidepressant dose), the risk is approximately 0.1%, comparable to other antidepressants. At 450mg daily (the maximum approved dose), the risk increases to approximately 0.4%. Risk factors that lower the seizure threshold include eating disorders (bulimia, anorexia), alcohol withdrawal, benzodiazepine withdrawal, a history of seizures, and head trauma. Wellbutrin is contraindicated in adults with active eating disorders or seizure disorders for this reason.
Wellbutrin is one of the few antidepressants associated with weight loss rather than weight gain. The dopaminergic mechanism tends to suppress appetite mildly. This makes it particularly attractive for adults who have experienced weight gain on SSRIs like sertraline or Lexapro. However, the weight loss effect is typically modest (2-5 pounds) and varies significantly between individuals.
Wellbutrin may be a particularly good fit when depression is accompanied by fatigue, low motivation, or difficulty concentrating (its activating properties address these symptoms directly), when sexual dysfunction from SSRIs is unacceptable, when weight gain from other medications is a concern, when ADHD co-occurs with depression, or when seasonal depression is the primary pattern. It is often combined with an SSRI ("Wellbutrin augmentation") to address residual symptoms or offset SSRI-related sexual dysfunction. A psychiatric evaluation helps determine whether Wellbutrin's unique profile matches your specific symptom presentation.
Most adults notice some improvement in energy and motivation within the first 1-2 weeks, but full antidepressant effects typically take 4-6 weeks. The early activating effects (improved energy, better concentration) often appear before mood improvement, which can be encouraging but should not be mistaken for full response.
Wellbutrin is generally not first-line for anxiety disorders and can initially worsen anxiety due to its activating properties. However, some adults find that once depression lifts, their anxiety improves as well. For comorbid anxiety and depression, your psychiatrist may combine Wellbutrin with an anxiety-specific medication like buspirone or gabapentin.
Yes. Wellbutrin is the brand name for bupropion. It comes in three formulations: immediate-release (IR, taken 2-3 times daily), sustained-release (SR, taken twice daily), and extended-release (XL, taken once daily). Most prescribers prefer the XL formulation for convenience and more consistent blood levels.
Loss and bereavement follow recognizable emotional patterns — understanding the stages of grief can help normalize your experience.
This content is for informational purposes only and should not replace professional medical advice, diagnosis, or treatment. If you have questions about Wellbutrin, schedule an appointment with Elevate Psychiatry. We serve adults 18 and older through our Miami offices in Coconut Grove and Doral, as well as virtually throughout Florida.
